More trials meet norms under Indian tiered approval system amid calls for increased transparency
This article was originally published in SRA
India's health ministry has indicated that 14 of the ongoing clinical trials that were part of the remaining 107 studies that needed to be re-evaluated following a court directive have met all relevant aspects of safety and efficacy, and has recommended that these be allowed to continue in the country.
You may also be interested in...
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the anticancer while the originator's patent stands valid.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.